ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis (RA) and tocilizumab"

  • Abstract Number: 2548 • 2012 ACR/ARHP Annual Meeting

    Global Molecular Effects of Tocilizumab Therapy in Synovial Biopsies of Early Rheumatoid Arthritis Patients

    Julie Ducreux1, Adrien Nzeusseu Toukap2, Frédéric A. Houssiau1, Patrick Durez3 and Bernard Lauwerys3, 1Institut de Recherche Expérimentale et Clinique, Pôle de Maladies Rhumatismales, Université catholique de Louvain, Brussels, Belgium, 2Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, 3Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic, systemic autoimmune inflammatory disease that is characterized by the presence of inflammatory cytokines, including interleukin-6 (IL-6). Here, we…
  • Abstract Number: 431 • 2012 ACR/ARHP Annual Meeting

    Basic and Clinical Significance of Interleukin 6 (IL-6) in AA Amyloidosis with RA

    Kazuyuki Yoshizaki, Prabha Tiwari, Lokesh P. Tripathi, Shandar Ahmad, Kenji Mizuguchi, Teppei Nishikawa-Matsumura, Tomoyasu Isobe and Soken-Nakazawa J. Song, Osaka University, Osaka, Japan

    Background/Purpose: Cytokine-induced hepatic serum amyloid A (SAA) is associated with the pathogenesis of AA amylodosis, a fatal disease with deposition of AA amyloid fibril on…
  • Abstract Number: 2550 • 2012 ACR/ARHP Annual Meeting

    Clinical, Radiographic, and Immunogenic Effects After 1 Year of Tocilizumab-Based Treatment Strategy with and without Methotrexate in Rheumatoid Arthritis: The ACT-RAY Study

    Maxime Dougados1, Karsten Kissel2, Philip G. Conaghan3, Emilio Martin-Mola4, Georg A. Schett5, Howard Amital6, Ricardo M. Xavier7, OM Troum8, Corrado Bernasconi9 and T.W.J. Huizinga10, 1Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland, 3University of Leeds, Leeds, United Kingdom, 4Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 5Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 6Sheba Medical Center, Tel-Hashomer, Israel, 7Rheumatology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 8Medicine, USC Keck School of Medicine, Santa Monica, CA, 9Consultant, Basel, Switzerland, 10Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: 24-week data from ACT-RAY comparing an add-on strategy (tocilizumab [TCZ] + methotrexate [MTX]) with a switch strategy (TCZ + placebo [PBO]) in MTX-IR patients…
  • Abstract Number: 444 • 2012 ACR/ARHP Annual Meeting

    Tocilizumab Improves Bone Mineral Density Compared with Abatacept in Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. an Open Label Randomized Controlled Trial

    Kensuke Kume1, Kanzo Amano1, Susumu Yamada1, Kazuhiko Hatta2, Kuniki Amano3, Noriko Kuwaba4 and Hiroyuki Ohta5, 1Rheumatology, Hiroshima Clinic, Hiroshima, Japan, 2Rheumatology, Hatta Clinic, Kure, Japan, 3Rheumatology, Sky Clinic, Hiroshima, Japan, 4Medical Research, Sanki Clinical Link, Hiroshima, Japan, 5Medical Research, hiroshima clinic, Hiroshima, Japan

    Background/Purpose: To compare the effect of tocilizumab(TCZ) plus methotrexate (MTX), with the effect of abatacept(ABT) plus MTX on bone mineral density(BMD) in TNF blockers resistant…
  • Abstract Number: 2505 • 2012 ACR/ARHP Annual Meeting

    Involvment of CD4+ FoxP3+ Regulatory T Cells in Interleukin-6 Receptor Targeted Treatment in Murine Arthritis and Rheumatoid Arthritis

    Allan Thiolat1, Jerome Biton1, Luca Semerano1, Yves-Marie Pers2, Pierre Portales2, Delphine Lemeiter1, Patrice Decker1, Christian Jorgensen2, Pascale Louis-Plence2, Natacha Bessis3 and Marie-Christophe Boissier4, 1EA4222, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, 93009, France, Bobigny, France, 2Department of therapy & Immuno-Rhumatology, Inserm U844, CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, Montpellier, France, 3INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, 4INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France

    Background/Purpose: Studies have demonstrated the clinical efficacy of tocilizumab, a humanized anti-IL-6 receptor (R) antibody (Ab), in patients with rheumatoid arthritis (RA). The rational for…
  • Abstract Number: L8 • 2012 ACR/ARHP Annual Meeting

    A Randomized, Double-Blind, Parallel-Group Study of the Safety and Efficacy of Tocilizumab Subcutaneous Versus Placebo in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis (BREVACTA)

    Alan J. Kivitz1, Ewa Olech2, Michael A. Borofsky3, Beatriz M. Zazueta4, Federico Navarro-Sarabia5, Lucy Rowell6, Clare Nasmyth-Miller6 and Janet E. Pope7, 1Altoona Center for Clinical Research, Duncansville, PA, 2Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV, 3Clinical Research Center of Reading, Reading, PA, 4Reumatologia, Centro de Investigacion en Enfermedades Reumaticas, Mexicali, Mexico, 5Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, 6Roche, Welwyn Garden City, United Kingdom, 7Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada

    Background/Purpose: The intravenous formulation of tocilizumab (TCZ) has demonstrated efficacy with a manageable safety profile in patients (pts) with rheumatoid arthritis (RA) in multiple clinical…
  • « Previous Page
  • 1
  • …
  • 6
  • 7
  • 8
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology